Assessing LncRNA DQ786243 and IL-17 Expression in Oral Lichen Planus: A Case Control Study
1 other identifier
observational
52
1 country
1
Brief Summary
Observational case-control study. The current study aims to assess the salivary expression of lncRNA DQ786243 and IL-17 in OLP, to better understand the pathogenesis of OLP and provide effective targets for OLP therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 5, 2020
CompletedFirst Submitted
Initial submission to the registry
August 5, 2020
CompletedFirst Posted
Study publicly available on registry
August 7, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 29, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 29, 2021
CompletedAugust 7, 2020
August 1, 2020
1.5 years
August 5, 2020
August 5, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Salivary expression of lncRNA DQ786243. Salivary expression of lncRNA DQ786243. Salivary expression of lncRNA DQ786243. Salivary expression of lncRNA DQ786243. ▪ Salivary expression of IL-17 and Salivary expression of lncRNA DQ786243.
one year
Study Arms (4)
Group IIa: 13 papular OLP
Group IIb: 13 atrophic OLP
Group IIc: 13 erosive OLP
Group I: 13 healthy individuals
Interventions
Salivary expression of lncRNA DQ786243 and IL-17 will be evaluated using qRT-PCR.
Eligibility Criteria
thestudy composes of two groups: healthy controls and OLP. The expression of the two markers will be compared between the two studied groups. In OLP group, the expression of the two markers will be correlated with pain and clinical assessment scores. In addition, OLP group will be subgrouped based on the clinical form: papular, atrophic, erosive. Data of all participants will be entered on Excel sheet. Each participant will be provided an ID number that will be used for data management and placed as a label for the samples. Group I: 13 healthy individuals Group IIa: 13 papular OLP Group IIb: 13 atrophic OLP Group IIc: 13 erosive OLP
You may qualify if:
- Patients diagnosed with OLP.
- Patient who will agree to participate in the study.
- Patients who will accept to sign the informed consent.
You may not qualify if:
- Patients suffering from any systemic disease.
- Patients suffering from any local inflammatory disease or infection.
- Pregnant and lactating women. ▪ Smokers.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
Cairo University
Cairo, 12223, Egypt
Related Publications (1)
Abdeldayem E, Rashed L, Ali S. Salivary expression of lncRNA DQ786243 and IL-17 in oral lichen planus: case-control study. BMC Oral Health. 2022 Jun 18;22(1):240. doi: 10.1186/s12903-022-02277-0.
PMID: 35717182DERIVED
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- assistant lecterur
Study Record Dates
First Submitted
August 5, 2020
First Posted
August 7, 2020
Study Start
January 5, 2020
Primary Completion
June 29, 2021
Study Completion
July 29, 2021
Last Updated
August 7, 2020
Record last verified: 2020-08